{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:44:31Z","timestamp":1780368271810,"version":"3.54.1"},"reference-count":43,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T00:00:00Z","timestamp":1358985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Early Intervention Psych"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Potential differences in psychiatric clinical outcomes and hospitalization rates before and after the initiation of long\u2010acting risperidone among recently and long\u2010term diagnosed schizophrenia patients were studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from two observational studies (Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (<jats:styled-content style=\"fixed-case\">TIMORES<\/jats:styled-content>) and electronic Schizophrenia Treatment Adherence Registry (<jats:styled-content style=\"fixed-case\">e<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">STAR<\/jats:styled-content>)) were categorized by the recency of their diagnose and compared in several <jats:italic>post hoc<\/jats:italic> analyses. <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>linical <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>lobal <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>mpression of illness <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>everity (<jats:styled-content style=\"fixed-case\">CGI<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>) and <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>lobal <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>ssessment of <jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>unctioning (<jats:styled-content style=\"fixed-case\">GAF<\/jats:styled-content>) scores, as well as symptoms of clinical deterioration (including hospitalization data) at baseline, 12\u2010month (for <jats:styled-content style=\"fixed-case\">TIMORES<\/jats:styled-content> and e\u2010<jats:styled-content style=\"fixed-case\">STAR<\/jats:styled-content>) and 24\u2010month (for <jats:styled-content style=\"fixed-case\">e<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">STAR<\/jats:styled-content>) follow\u2010up were analysed. Other outcome measures included discontinuation rate, employment status and remission attainment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Statistically significantly differences between recent and long\u2010term diagnosed schizophrenic patients at 12\u2010 and 24\u2010month follow\u2010up were found for <jats:styled-content style=\"fixed-case\">CGI<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content> (between <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01 and <jats:italic>P<\/jats:italic>\u2009\u2264\u20090.001) and <jats:styled-content style=\"fixed-case\">GAF<\/jats:styled-content> (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) scores. Other differences between both schizophrenic patient groups were found for measures of clinical deterioration, employment status and full symptomatic remission rates at 1 year. Although no consistent difference was found between recent and long\u2010term patient groups for hospitalization parameters, the difference in length of full hospitalization days was statistically significantly different (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) between <jats:styled-content style=\"fixed-case\">e<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">STAR<\/jats:styled-content> \u2018Early\u2019 and \u2018Late\u2019 patient groups at both 12\u2010 and 24\u2010month endpoints: the mean change from baseline was significantly greater for <jats:styled-content style=\"fixed-case\">e<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">STAR<\/jats:styled-content> \u2018Early\u2019 at 12 months, but greater for <jats:styled-content style=\"fixed-case\">e<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">STAR<\/jats:styled-content> \u2018Late\u2019 at 24 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The findings of the <jats:italic>post hoc<\/jats:italic> analyses support the significance of pharmacological interventions, such as long\u2010acting risperidone, in addressing discontinuity issues, especially in recently diagnosed patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/eip.12017","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T14:08:27Z","timestamp":1359036507000},"page":"39-49","source":"Crossref","is-referenced-by-count":15,"title":["Clinical outcomes of long\u2010acting risperidone in recent versus long\u2010term diagnosed <scp>B<\/scp>elgian schizophrenic patients: results from electronic <scp>S<\/scp>chizophrenia <scp>T<\/scp>reatment <scp>A<\/scp>dherence <scp>R<\/scp>egistry (<scp>e<\/scp>\u2010<scp>STAR<\/scp>) and <scp>T<\/scp>rial for the <scp>I<\/scp>nitiation and <scp>M<\/scp>aintenance Of <scp>RE<\/scp>mission in <scp>S<\/scp>chizophrenia with risperidone (<scp>TIMORES<\/scp>)"],"prefix":"10.1111","volume":"8","author":[{"given":"Vincent","family":"Dubois","sequence":"first","affiliation":[{"name":"Service de Psychiatrie Adulte Cliniques Universitaires St Luc  Bruxelles Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Peuskens","sequence":"additional","affiliation":[{"name":"Campus Kortenberg UPC KU Leuven  Kortenberg Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Geerts","sequence":"additional","affiliation":[{"name":"Medical Affairs Department Janssen  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Detraux","sequence":"additional","affiliation":[{"name":"Campus Kortenberg UPC KU Leuven  Kortenberg Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.04.011"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.01.022"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2010.11.010"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291708003449"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.09.021"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.9.975"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.10.020"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1017\/S003329170800514X"},{"key":"e_1_2_7_10_1","unstructured":"CaseM StaufferVL Ascher\u2010SvanumHet\u2009al.The heterogeneity of antipsychotic response in the treatment of schizophrenia. Poster presented at the SIRS (Schizophrenia International Research Society) Congress at Florence Italy 10\u201314 April 2010."},{"issue":"9","key":"e_1_2_7_11_1","first-page":"s5","article-title":"Factors influencing treatment response and outcome of first\u2010episode schizophrenia: implications for understanding the pathophysiology of schizophrenia","volume":"57","author":"Lieberman JA","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.3.241"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033315"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.7090su1cj"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.11.020"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/11537680-000000000-00000"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903149306"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903488670"},{"key":"e_1_2_7_19_1","first-page":"34","article-title":"Long\u2010acting Risperidone in the treatment of schizophrenia: data from a 24\u2010month Belgian electronic Schizophrenia Treatment Adherence Registry (e\u2010STAR)","volume":"110","author":"Peuskens J","year":"2010","journal-title":"Acta Psychiatr Belg"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32830c2042"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2008.03.012"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05284yel"},{"key":"e_1_2_7_23_1","first-page":"9","article-title":"Long\u2010acting risperidone in early\u2010episode schizophrenia","volume":"111","author":"Dubois V","year":"2011","journal-title":"Acta Psychiatr Belg"},{"key":"e_1_2_7_24_1","unstructured":"PeuskensJ DuboisV GeertsP DetrauxJ.Clinical outcomes of long\u2010acting risperidone in recent versus long\u2010term diagnosed Belgian schizophrenic patients: results from e\u2010STAR (Electronic Schizophrenia Treatment Adherence Registry). Poster presented at the 7th International Conference on Early Psychosis 28 November\u20131 December 2010 Amsterdam The Netherlands."},{"key":"e_1_2_7_25_1","volume-title":"DSM\u2010IV\u00ae\u2010TR. Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2003"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2143\/TVG.58.11.5001342"},{"key":"e_1_2_7_27_1","unstructured":"Van AudenhoveC Van HumbeeckG Van MeerbeeckA.De vermaatschappelijking van de zorg voor psychisch kwetsbare mensen. Onderzoek praktijk en beleid. LannooCampus Leuven;2005."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa002028"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.107.s416.5.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2004.00450.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.3.441"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.4.600"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.4.611"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60486-9"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.7.1050"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.12.020"},{"issue":"2","key":"e_1_2_7_38_1","first-page":"s236","article-title":"Direct switching to risperidone long\u2010acting injectable: experience in patients early in the course of the disease","volume":"7","author":"Christensen TB","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_7_39_1","unstructured":"ChristensenTB KisslingWK MedoriR.Long\u2010acting risperidone in patients with early psychosis \u2013 less than 1 year duration. Poster presented at the World Psychiatric Association (WPA) International Congress Istanbul Turkey 12\u201316 July 2006."},{"key":"e_1_2_7_40_1","doi-asserted-by":"crossref","unstructured":"NapryeyenkoO BurbaB MartinezGet\u2009al.Efficacy and tolerability among patients with recent\u2010onset schizophrenia treated with long\u2010acting injectable risperidone (RLAI). Poster presented at the 9th World Congress of Biological Psychiatry (WCBP) Paris France June 28\u2013July 2 2009.","DOI":"10.1016\/j.schres.2010.02.943"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105056513"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e328336c93f"},{"key":"e_1_2_7_43_1","unstructured":"SaleemPT FirminoH PsiquiatriaS ParelladaE SchreinerA M\u00f6llerH\u2010J.Young patients (18\u201330 years) with schizophrenia and schizoaffective disorder: results of direct switching to long\u2010acting injectable risperidone (StoRMi trial). Poster presented at the twelfth winter workshop on schizophrenia Davos Switzerland 7\u201313 February 2004."},{"key":"e_1_2_7_44_1","unstructured":"MacfaddenW BossieC TurkozIet\u2009al.Effect of long\u2010acting injectable risperidone on clinical outcomes in recently diagnosed stable schizophrenia patients. Poster presented at the 60th Annual Meeting of the American Psychiatric Association (APA) Institute on Psychiatric Services (IPS) Chicago Illinois USA 2\u20135 October 2008."}],"container-title":["Early Intervention in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Feip.12017","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eip.12017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T10:47:41Z","timestamp":1696330061000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/eip.12017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,24]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1111\/eip.12017"],"URL":"https:\/\/doi.org\/10.1111\/eip.12017","archive":["Portico"],"relation":{},"ISSN":["1751-7885","1751-7893"],"issn-type":[{"value":"1751-7885","type":"print"},{"value":"1751-7893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,24]]}}}